Salvage treatment with lopinavir.ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families

HIV Clinical Trials

Volumn 3, Issue 4, 2002, Pages 304-309

  de Mendoza, Carmen ^a   Martín Carbonero, Luz ^a   Barreiro, Pablo ^a   Diaz, Beatriz ^a   Valencia, Eulalia ^a   Jiménez Nácher, Inmaculada ^a   Gallego, Oscar ^a   Núñez, Marina ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Drug resistance; HIV; Lopinavir; Protease inhibitors; Toxicity

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHOLESTEROL; EFAVIRENZ; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; PYRIMIDINONE DERIVATIVE; RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CODON; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; GENOTYPE; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RASH; SEQUENCE ANALYSIS; T LYMPHOCYTE; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS MUTATION; ANTIBIOTIC RESISTANCE; CD4 LYMPHOCYTE COUNT; CLASSIFICATION; DRUG COMBINATION; DRUG EFFECT; GENETIC VARIABILITY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; SALVAGE THERAPY; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; PROTEASE INHIBITORS; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; SALVAGE THERAPY; VARIATION (GENETICS);

EID: 0035986072     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/h5jn-mfg3-g35k-qx9j     Document Type: Article

References (16)

1. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
2. ABT-378/ritonavir versus nelfinavir in antiretroviral naive subjects: Week 48 comparison in a phase III blinded randomised clinical trial (study 863)
3. trough inhibitory quotient predicts virologic response to ABT-378/ritonavir therapy in treatment experienced patients
4. Safety and antiviral activity at 48 weeks of lopinavir/ritoanvir plus nevirapine and 2 NRTI in HIV-1-infected protease inhibitor-experienced patients
5. ABT-378/ritonavir and efavirenz: One year safety/efficacy evaluation in multiple PI-experienced patients (study 957)
6. Kaletra and efavirenz: One year safety/efficacy evaluation and phenotypic breakpoints in multiple PI-experienced patients
7. A branched DNA signal amplification assay for quantitation of nucleic acid targets below 100 molecules/ml
8. Treatment of high blood cholesterol in adults
9. Genotypic correlates of reduced in vitro susceptibility to ABT-378 in HIV isolates from patients failing protease inhibitor therapy
10. Antiretroviral resistance mutations. Revised April 2001
11. Initial efficacy results from the Kaletra early access program
12. Response to lopinavir-based multidrug rescue regimens
13. Evaluation of ABT-378/ritonavir based salvage regimens in a cohort of HIV-infected patients
14. Identification of individual mutations in HIV protease associated with virological response to lopinavir/ritonavir therapy
15. Analysis of the correlation between baseline genotypic profile and virological response to lopinavir/ritonavir in 104 multiple PI-experienced patients treated under the expanded access program
16. HIV-1 genotypic determinants of the virologic response to lopinavir/ritonavir-containing therapy in PI-experienced patients